Skip To Main Content
Yeelon Yeoh on Muck Rack

Yeelon Yeoh

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yeelon

Contact Yeelon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A recent update on small‐molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry‐based proteomic analysis - Lee - 2023 - The FEBS Journal - Wiley Online Library

|
By Pey Yee Lee, Yeelon Yeoh
| Wiley Online Library Verified
Protein kinases as drug targets The FDA-approved small molecule KIs target more than 20 types of protein kinases. In the following, we briefly summarize selected targeted kinases, their respective inhibitors and the biological pathways involved. Whereas imatinib is the first-generation TKI targeting Bcr-Abl, the second-generation Bcr-Abl TKIs including dasatinib, bosutinib and nilotinib were approved for patients with imatinib resistance [[34]].
Open in Who Shared Issue with article?
See all 1 articles